source
- Novartis halts Phase 2 lupus nephritis trial of Fabhalta, cites strategic reasonsNovartis has stopped a Phase 2 study of its complement blocker Fabhalta (iptacopan) in patients with lupus nephritis, a kidney involving form of the disease. The company said the decision was base…
- Measles resurgence threatens Republican midterm prospects, physicians warnPhysicians and former Republican congressmen Larry Bucshon and Michael C. Burgess wrote an opinion piece warning that the recent measles surge is turning into a political liability for the GOP. Va…